Sanofi (SNY)

NASDAQ: SNY · Real-Time Price · USD
49.90
+0.32 (0.65%)
Sep 3, 2025, 4:00 PM - Market closed
0.65%
Market Cap120.17B
Revenue (ttm)53.71B
Net Income (ttm)10.72B
Shares Out 1.22B
EPS (ttm)8.65
PE Ratio5.78
Forward PE10.40
Dividend$1.60 (3.20%)
Ex-Dividend DateMay 9, 2025
Volume1,944,734
Open49.83
Previous Close49.58
Day's Range49.74 - 50.36
52-Week Range44.73 - 60.12
Beta0.41
AnalystsBuy
Price Target65.00 (+30.26%)
Earnings DateOct 24, 2025

About SNY

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange NASDAQ
Ticker Symbol SNY
Full Company Profile

Financial Performance

In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.

Financial numbers in EUR Financial Statements

Analyst Summary

According to 3 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $65.0, which is an increase of 30.26% from the latest price.

Price Target
$65.0
(30.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

1 hour ago - Reuters

Now Is The Time To Buy This High-Yielding Trio

The focus of today will be on CMCSA, AES, and SNY. The trifecta provides a reasonably secure 4.5% average yield, an A- average S&P credit rating, and is 33% undervalued. Comcast Corporation could be s...

Other symbols: AESCMCSA
4 days ago - Seeking Alpha

US FDA approves Sanofi's drug for a rare blood disorder

The U.S. Food and Drug Administration has approved Sanofi's drug to treat a type of blood disorder, the company said on Friday, in a sign that the French drugmaker's $3.7 billion bet on the treatment ...

4 days ago - Reuters

Press Release: Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia

Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA...

4 days ago - GlobeNewsWire

Press Release: Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease

Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...

20 days ago - GlobeNewsWire

Sanofi stops supply of high cholesterol drug to China due to limited availability

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French pharmaceuticals firm and its partner Regeneron Pharmaceuticals, in China due to lim...

22 days ago - Reuters

Sanofi: Playing To Win

Sanofi's strategic pivot to immunology and rare diseases, plus AI-driven R&D, targets higher margins and sustainable long-term growth. Blockbuster drugs like Dupixent, Altuviiio, and Beyfortus, alongs...

27 days ago - Seeking Alpha

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”).

4 weeks ago - GlobeNewsWire

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

4 weeks ago - WSJ

European drugmakers fall after Trump raises stakes over US drug price cuts

Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...

Other symbols: AZNMRKNVO
4 weeks ago - Reuters

Sanofi (SNY) Q2 2025 Earnings Call Transcript

Sanofi (NASDAQ:SNY) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Brian Foard - Executive VP & Head of Specialty Care François-Xavier Roger - Executive VP & CFO Houma...

4 weeks ago - Seeking Alpha

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...

4 weeks ago - Forbes

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.

4 weeks ago - CNBC Television

Trump pressures 17 pharma CEOs to cut US drug prices

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...

4 weeks ago - Reuters

Trump posts letters to 17 pharmaceutical companies about drug prices

CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.

4 weeks ago - CNBC Television

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...

4 weeks ago - CNBC

Press release: Online availability of Sanofi's half-year financial report for 2025

Online availability of Sanofi's half-year financial report for 2025 Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and ...

4 weeks ago - GlobeNewsWire

Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales

Sanofi SA  SNY reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.

4 weeks ago - Benzinga

Sanofi CEO Paul Hudson on Q2 results, Dupixent demand and tariff impact

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong demand for Dupixent, drug pipeline outlook, impact of tariffs, and more.

4 weeks ago - CNBC Television

Sanofi revises annual sales growth expectations on strong Dupixent demand

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer tr...

4 weeks ago - Reuters

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range.

4 weeks ago - GlobeNewsWire

Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment...

5 weeks ago - GlobeNewsWire

U.S. and European Union trade deal could cost the pharma industry up to $19 billion

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...

5 weeks ago - Fast Company

EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...

5 weeks ago - Reuters

Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

5 weeks ago - GlobeNewsWire